Shots:

• Second Genome will receive $38M as upfront- up to $300M milestones for each of five target discovery programs and royalties for approved therapies. Additionally- it will receive milestones for each validated biomarker delivered under the collaboration
• The collaboration will deploy Second Genome’s Microbiome Analytics Platform to identify biomarkers associated with clinical response in up to 5 of Gilead’s pipeline compounds in inflammation- fibrosis and other diseases and to identify up to 5 novel therapies targeting IBD over the next 4yrs.- with an option to extend the collaboration for an additional 2yrs.
• Gilead to get the global option rights for up to 5 programs targeting all diseases along with exclusive rights to all biomarkers developed under the collaboration

Click here ­to­ read full press release/ article 

Ref: Gilead | Image:Gilead